ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1132

Association Between Serum Selenium Level and the Prevalence of Osteoarthritis: Data from the Xiangya Osteoarthritis Study

Ning Wang1, Mingsheng Xie1, Chao Zeng2, Tubao Yang1, Zidan Yang1, Yilun Wang1, Jiatian Li1, Jian Tian1, Tuo Yang1 and Guanghua Lei1, 1Central South University, Changsha, China (People's Republic), 2Central South University, Chang Sha, China (People's Republic)

Meeting: ACR Convergence 2021

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Osteoarthritis – Clinical Poster III (1118–1134)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Selenium plays an indispensable role in the process of antioxidant and antiinflammation. Oxidative stress and inflammation have been hypothesized to be involved in the pathogenesis of cartilage degeneration. We sought to explore the association between serum selenium levels and the prevalence of radiographic osteoarthritis (ROA) in a large population-based study.

Methods: Subjects aged 50 years or older were from the Xiangya Osteoarthritis (XO) Study, a community-based observational study. Serum selenium concentration was measured by inductively coupled plasma-dynamic reaction cell-mass spectrometry. ROA was defined as a Kellgren/Lawrence score ≥ 2 for at least one knee, hip or hand joint. The association between serum selenium levels and ROA were evaluated by conducting logistic and spline regression.

Results: A total of 1,032 participants (women: 52.5%; mean age: 63.1 years; ROA prevalence: 45.4%) were included. Compared with the lowest tertile, odds ratios (ORs) for ROA were 0.69 (95% confidence interval [CI]: 0.51 to 0.93) and 0.56 (95% CI: 0.41 to 0.75) in the second and third tertiles of serum selenium, respectively (P for trend < 0.05) (Table 1). Adjusting for potential confounders did not change the results materially. In addition, subjects with lower serum selenium levels had a higher prevalence of OA in a dose-response-relationship manner (P = 0.005) (Figure 1).

Conclusion: Subjects with lower levels of serum selenium, even within the normal range, had higher prevalence of ROA in a dose-response relationship manner, suggesting that selenium may have a preventive or therapeutic potential for OA.

Table 1. Association between serum selenium levels and radiographic knee, hip or hand ROA (1,032 participants)

Figure 1. Dose-response relationship between serum selenium level and the odds ratio (OR) for radiographic knee, hand or hip radiographic osteoarthritis (ROA). CI, confidence interval.


Disclosures: N. Wang, None; M. Xie, None; C. Zeng, None; T. Yang, None; Z. Yang, None; Y. Wang, None; J. Li, None; J. Tian, None; T. Yang, None; G. Lei, None.

To cite this abstract in AMA style:

Wang N, Xie M, Zeng C, Yang T, Yang Z, Wang Y, Li J, Tian J, Yang T, Lei G. Association Between Serum Selenium Level and the Prevalence of Osteoarthritis: Data from the Xiangya Osteoarthritis Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/association-between-serum-selenium-level-and-the-prevalence-of-osteoarthritis-data-from-the-xiangya-osteoarthritis-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-serum-selenium-level-and-the-prevalence-of-osteoarthritis-data-from-the-xiangya-osteoarthritis-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology